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SESSION II
METHODOLOGY ISSUES
PMI1
FROM HEALTH-RELATED QOL TO UTILITY—
IS THERE A WAY?
Svensson K1, Szende A2, Ståhl E1, Lundbäck B3
1AstraZeneca R&D Lund, Sweden, Lund, Sweden; 2Medtap
International, Jisp, Netherlands; 3University Hospital, Umeå,
Sweden
OBJECTIVE: To predict utility values from health-related
quality of life (HRQL) assessments could, if possible, 
be a fruitful way to use HRQL assessments for health 
economic evaluations. With this in mind, we compared
values for SF-6D, an index derived from the domain
values of SF-36 by an algorithm from Brazier et al., 
with values from the EuroQol instrument, the EQ-5D
index, and the EQ-VAS (Visual Analog Scale).
METHODS: Data from two surveys of patients with res-
piratory disease were used in this comparison. The ﬁrst
data set was from 120 patients in the northern part of
Sweden with COPD, and the other dataset from 206
patients in Hungary suffering from asthma. Both surveys
covered patients with different severity of the disease. The
two datasets were analyzed separately. The EQ-VAS
values were rescaled from a range of 0–100 to a 0–1
range.
RESULTS: Results are consistent for the two different
data sets and shows an expected gradient for severity
groups in both cases. SF-6D has on the average slightly
lower values than EQ-5D but higher than EQ-VAS (Mean
for COPD: 0.74 vs 0.78 and 0.65; ASTHMA: 0.69 vs.
0.70 and 0.62). On the other hand, both EQ-5D and EQ-
VAS have larger variation with a substantial proportion
of patients reaching maximum or minimum achievable
values. Correlations between the different indices are
deceptively high because of extreme values (r for COPD:
0.75–0.69; ASTHMA: 0.70–0.49).
CONCLUSION: SF-6D shows a response pattern more
in line with intuitive expectation than EQ-5D and EQ-
VAS, which both seem to have a ceiling (and ﬂoor)
problem.
PMI2
ESTIMATING PREVALENCE AND SURVIVAL BY
STAGE OF CANCER FROM THE US SEER
DATABASE: COLORECTAL CANCER
Koo LC1, Lally CA2
1AstraZeneca, Wilmington, DE, USA; 2Emory University,
Atlanta, GA, USA
OBJECTIVE: To understand disease burden, prognosis,
and survival, and estimate target patient populations for
treatment, knowing the prevalence of patients by their
clinical stage of disease (AJCC/UICC/TNM) is important.
However, such data is not readily available in the pub-
lished SEER (Surveillance, Epidemiology and End
Results) statistics. Moreover, the SEER deﬁnitions for
staging cancer into local, regional, and distant has
changed from 1973–98, and do not coincide with the
AJCC clinical stages of I, II, III, and IV. The latter has
also undergone ﬁve editions from 1978–1997. Colorectal
cancer is the third most common incident cancer in the
US, with good prognosis and survival if detected early.
We estimated the prevalence and survival of colorectal
cancer by clinical stage.
METHODS: From the August 2001 release of the SEER
database, there were 281,940 cases with a diagnosis of
colorectal cancer and complete follow-up through
December 31, 1998. The different staging systems of
AJCC, TNM, SEER 2000, SEER 1977, SEER Historic
Coding, and Dukes/Astler-Collins were summarized and
compared, showing the differences and the overlap in the
staging systems. Colorectal cancer cases diagnosed from
1988–1998 (n = 129,664) were recoded to the AJCC
coding system by SEER. In order to estimate age-adjusted
prevalence by stage for the year 2001, we calculated the
1998 age speciﬁc prevalence. This latter ﬁgure was stan-
dardized to the 1990 US standard population to estimate
the age-adjusted prevalence, which was then projected
onto the 2001 US population estimates to calculate an
estimated age-adjusted prevalence in 2001 by stage of
disease.
RESULTS: The estimated year 2001 prevalence of col-
orectal cancer and median survival by AJCC stage were:
Stage I, n = 228,958, 9.7yrs.; Stage II, n = 223,936, 
6.7yrs.; Stage III, n = 145,307, 3.9yrs.; and Stage IV, 
n = 28,009, 0.8yrs.
CONCLUSION: Colorectal cancer in the US was found
to have decreasing prevalence and survival with increas-
ing clinical stage (severity).
PMI3
DEVELOPMENT OF DESCRIPTIONS OF
TREATMENTS FOR COLORECTAL CANCER FOR
USE IN PREFERENCE MEASUREMENT
Wild D1, Grove A1, Hakim Z2, Kind P3
1Oxford Outcomes, Headington, Oxford, UK; 2Roche
Pharmaceuticals, Nutley, NJ, USA; 3University of York,
Heslington,York, UK
OBJECTIVE: When using non-patients as respondents 
in health state preference measurement, it is necessary 
to develop accurate descriptions of treatment alternatives
and health states patients may be likely to experience. We
developed descriptions of commonly used treatment
modalities for colorectal cancer (CRC) and ensuing health
states for use in subsequent preference measurement
studies.
METHODS: Following a literature review and clinical
expert input, we identiﬁed four commonly used treatment
modalities for CRC. Clinical data for each of the modal-
ities were abstracted from the literature, and reviewed by
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oncologists to conﬁrm if the literature descriptions of 
the modalities were consistent with experience in clinical
practice. Draft descriptions were then prepared, and crit-
ically reviewed by patients from each of the treatment
modalities for not only accuracy and relevance but 
also comprehensibility. Patients were also speciﬁcally
instructed in these qualitative interviews to describe the
impact of their treatment modalities on their everyday
lives, to ensure that the ensuing descriptions captured rel-
evant patient outcomes and were phrased in language
used by patients. Finally, interviews were carried out 
with lay persons to review the descriptions for clarity and
comprehensibility.
RESULTS: The three commonly used treatment modali-
ties for CRC were Modiﬁed de Gramont, Mayo, and
Xeloda. It was decided to describe each modality in terms
of efﬁcacy, adverse events, administration procedures,
and patient outcomes. For ease of comprehension, pa-
tients and lay persons suggested presenting the informa-
tion in separate sections. Subjects were satisﬁed that the
ensuing descriptions accurately captured the relevant
issues and were comprehensible.
CONCLUSION: We have successfully prepared accurate
and comprehensible descriptions of treatment modalities
and ensuing health states in CRC. These descriptions may
be useful in health state preference measurement studies
using non-patients as respondents.
PMI4
ASSESSING RESOURCE USE WITHIN
ONCOLOGY INDICATIONS:A
METHODOLOGICAL APPROACH TO
CONDUCTING RETROSPECTIVE DATA
ANALYSES
Semroc G1, Tierce J2, Stolshek B3
1Epinomics Research, Inc, San Diego, CA, USA; 2Epinomics
Research, Inc, Alexandria,VA, USA; 3Amgen,Thousand Oaks,
CA, USA
Reimbursement and other health policy decisions may be
highly inﬂuenced by analysis of claim-based utilization.
Secondary analyses of medical claims data to describe
patterns of resource utilization often rely on arbitrarily
deﬁned timeframes. In oncology, where treatment is in
short deﬁned time periods, both simple use-per-time 
averaging and illness-episode approaches based on
primary diagnosis and treatment may inaccurately esti-
mate resource utilization.
OBJECTIVE: This study examined the variation in uti-
lization of an injectable oncology supportive care agent
using three different analytical techniques.
METHODS: Patients with a principal diagnosis of cancer
and use of ﬁlgrastim were extracted from the 1996–98
Medicare 5% claims database. Patterns of resource 
utilization were compared with 1) simple use-per-time 
averaging; 2) illness-episode aggregation; and 3) per-
chemotherapy cycle aggregation. Descriptive statistics for
the number of days of utilization are reported.
RESULTS: A total of 5,160 patients yielding 2.9 million
claims were analyzed. The range of ﬁlgrastim resource
utilization varied considerably depending on the analysis
technique used: simple use-per-time was 1 to 159 days;
illness-episode aggregation was 1 to 51 days; and per-
chemotherapy cycle aggregation was 1 to 15 days. For all
analyses, the medical claims data do not provide adequate
rationale for use or days of utilization, and therefore this
database has limited value as a guide to future decision-
making. In addition, the analysis was limited in the ability
to accurately identify chemotherapy regimens; differenti-
ate prophylactic vs. treatment use of supportive agents;
and in describing oral chemotherapy use, dose delays and
reductions, and reasons for chemotherapy alterations.
CONCLUSION: Resource utilization in oncology is
highly inﬂuenced by the data source and the analysis
method chosen, which may not allow for an accurate
understanding of practice patterns. Only by understand-
ing these limitations in speciﬁc disease areas can the
medical decision-making be improved leading to better
patient outcomes.
PMI5
FACTORS FOR THE VARIATION IN THE
PREVALENCE OF ARTERIAL PERIPHRIAL
DISEASE—STUDY IMPLICATIONS FOR
OUTCOMES RESEARCH
Wang AY
Pﬁzer Inc, Ann Arbor, MI, USA
Prevalence of peripheral arterial disease (PAD) has been
constantly grown over the past decades. However, in-
consistent data on PAD prevalence from published liter-
ature were limited in use for either research or disease
management.
OBJECTIVES: The purposes of this review were to sum-
marize published PAD prevalence and to identify factors
that may cause the variation in PAD prevalence.
METHODS: English-language studies published between
1980 to December 2001 were identiﬁed through a
MEDLINE search.
RESULTS: Thirty-one studies on PAD prevalence were
identiﬁed. The present review showed that the prevalence
of PAD varied and it was highly dependent on the deﬁn-
ition of clinical presentations. Additional factors for the
variation included type, sensitivity and/or speciﬁcity of
diagnostic tests for screening and the distribution of risks
for PAD including age, male gender, smoking, diabetes
and dyslipidemia. The review showed that the prevalence
of PAD varied ranging from 1.2% in general population
to 29% in high-risk patients. After adjusting for age,
gender and clinical presentation, the overall PAD preva-
lence and the prevalence with intermittent claudication
were 8.7% to 26.5% and 1.6% to 2.9% respectively.
Prevalence of PAD was often higher (2 to 7 times) in
studies using a combination of noninvasive tests, patient
reported history and physical examinations for diagnosis
than that in those studies using only patient history plus
